Kailera Therapeutics, Inc.
KLRA
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for obesity and related metabolic conditions. Kailera Therapeutics advances a diversified pipeline of injectable and oral product candidates built around GLP-1-based mechanisms, including programs that target GLP-1, GIP, and glucagon pathways. Its portfolio is designed to address different patient needs in obesity care through multiple routes of administration and varying dosing approaches. The company’s lead program, ribupatide, is a once-weekly injectable GLP-1/GIP dual agonist being evaluated in late-stage clinical development. Kailera Therapeutics also works on oral small-molecule and peptide candidates that expand its treatment options across the weight-management market. Based in Waltham, Massachusetts, Kailera Therapeutics serves the biotechnology and metabolic disease sectors with a focus on modern obesity care.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
Net Income (FY)
-$149M
Op. Margin
–
ROIC
-1163.29%
Cash Flow & Balance Sheet
FCF (FY)
-$122M
Op. Cash Flow (FY)
-$120M
Net Debt
-$535M
Net Cash Position
Cash & Equiv.
$546M
Continue Research
Peers
Biotechnology · Pick stocks to compare with KLRA
Held by ETFs
KLRA is in 9 US ETFs. The largest of them, with KLRA's weight in each:
Vanguard Small-Cap Growth ETFVBK0.01%of the fund
iShares Russell 2000 Growth ETFIWO0.03%of the fund
State Street SPDR S&P Biotech ETFXBI0.16%of the fund
Fidelity Blue Chip Growth ETFFBCG0.01%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.02%of the fund
JPMorgan BetaBuilders U.S. Small Cap Equity ETFBBSC0.03%of the fund
Kailera Therapeutics (KLRA) in two numbers
Questions about Kailera Therapeutics
Is Kailera Therapeutics a high-quality business?
Kailera Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$535M, and its weakest is return on capital at -1163.3%. The Quality tab shows every check against its target.
Does Kailera Therapeutics (KLRA) pay a dividend?
No. Kailera Therapeutics (KLRA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KLRA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.